Menu Search
Equities

Paul Hartmann AG

PHH2:STU

Paul Hartmann AG

Actions
  • Price (EUR)210.00
  • Today's Change1.00 / 0.48%
  • Shares traded4.00
  • 1 Year change+8.25%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Paul Hartmann AG is a Germany-based holding company that is principally engaged in the field of medical and healthcare products. The Company operates through four segments, namely Wound Management, Incontinence Management, Infection Management and Other Group Activities. The Wound Management segment comprises wound dressings, as well as products for compression treatment, immobilization, First Aid and diagnostic devices. The Incontinence Management segment includes absorbent products worn close to the body for incontinence hygiene, such as under pads for patients as well as patient hygiene products and medical skin care. The Infection Management segment covers a range of custom procedure trays, surgical draping systems, surgical clothing, and surgical and examination gloves as well as the disinfection assortment. The Other Group Activities includes activities in cotton-wool products, feminine hygiene, baby care, medical consumer goods and pharmaceutical products, among others.

  • Revenue in EUR (TTM)2.38bn
  • Net income in EUR59.53m
  • Incorporated1912
  • Employees10.05k
  • Location
    Paul Hartmann AGPaul-Hartmann-Strasse 12HEIDENHEIM 89522GermanyDEU
  • Phone+49 7321360
  • Fax+49 7 321363636
  • Websitehttps://www.hartmann.info/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.